Latest & greatest articles for hypertension

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hypertension or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hypertension and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hypertension

121. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.

Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. BACKGROUND: Previous randomised renal denervation studies did not show consistent efficacy in reducing blood pressure. The objective of our study was to evaluate the effect of renal denervation on blood pressure in the absence of antihypertensive medications. METHODS: SPYRAL HTN-OFF MED

Lancet2017

122. Does early detection of renovascular hypertension improve outcomes?

Does early detection of renovascular hypertension improve outcomes? Does early detection of renovascular hypertension improve outcomes? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Does early detection of renovascular hypertension improve outcomes? View/ Open Date 2017-05 Format Metadata Abstract Does early (...) detection of renovascular hypertension improve outcomes? Evidence-based answer: Probably not. Finding atherosclerotic renal artery stenosis (ARAS) and treating with revascularization has shown no clinically significant improvement in rates of myocardial infarction (MI), renal function, congestive heart failure (CHF), or stroke compared with medical treatment of renovascular hypertension (SOR: A, metaanalysis of RCTs). Recommendations to revascularize asymptomatic ARAS are controversial, calling

Evidence Based Practice 2017

123. Next steps for gene-identification in primary hypertension genomics

Next steps for gene-identification in primary hypertension genomics 28784647 2018 01 16 2018 11 13 1524-4563 70 4 2017 10 Hypertension (Dallas, Tex. : 1979) Hypertension Next Steps for Gene Identification in Primary Hypertension Genomics. 695-697 10.1161/HYPERTENSIONAHA.117.09719 Ehret Georg G From Cardiology, Department of Specialties of Medicine, Geneva University Hospitals, Switzerland; and Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins (...) University School of Medicine, Baltimore, MD. georg.ehret@hcuge.ch. eng R01 HL086694 HL NHLBI NIH HHS United States R01 HL128782 HL NHLBI NIH HHS United States Editorial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Comment 2017 08 07 United States Hypertension 7906255 0194-911X IM Hypertension. 2017 Oct;70(4):743-750 28784648 PLoS Genet. 2015 Mar 18;11(3):e1005035 25785607 Science. 2015 May 8;348(6235):660-5 25954002 J Clin Invest. 2014 Oct;124(10):4642-56 25244096 Hypertension

Hypertension (Dallas, Tex. : 1979)2017 Full Text: Link to full Text with Trip Pro

124. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial)

Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial) 28512184 2017 05 17 2017 08 17 2017 08 17 1524-4539 136 5 2017 Aug 01 Circulation Circulation Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial). 440-450 10.1161/CIRCULATIONAHA.117.028441 It is currently unknown whether intensive (...) blood pressure (BP) lowering beyond that recommended would lead to more lowering of the risk of left ventricular hypertrophy (LVH) in patients with hypertension and whether reducing the risk of LVH explains the reported cardiovascular disease (CVD) benefits of intensive BP lowering in this population. This analysis included 8164 participants (mean age, 67.9 years; 35.3% women; 31.2% blacks) with hypertension but no diabetes mellitus from the SPRINT trial (Systolic Blood Pressure Intervention Trial

EvidenceUpdates2017

125. Impact of Cardiorespiratory Fitness and Risk of Systemic Hypertension in Nonobese Versus Obese Men Who Are Metabolically Healthy or Unhealthy

Impact of Cardiorespiratory Fitness and Risk of Systemic Hypertension in Nonobese Versus Obese Men Who Are Metabolically Healthy or Unhealthy 28705382 2017 07 14 2017 08 15 1879-1913 120 5 2017 Sep 01 The American journal of cardiology Am. J. Cardiol. Impact of Cardiorespiratory Fitness and Risk of Systemic Hypertension in Nonobese Versus Obese Men Who Are Metabolically Healthy or Unhealthy. 765-768 S0002-9149(17)30955-4 10.1016/j.amjcard.2017.05.054 Few data are available regarding (...) the influence of body phenotype on systemic hypertension (SH) and whether cardiorespiratory fitness (CRF) attenuates this relation. We tested the hypothesis that obesity phenotypes and CRF would predict incident hypertension, evaluating 3,800 Korean men who participated in 2 health examinations in1998 to 2009. All participants were normotensive at baseline and were divided into 4 groups based on body mass index using the Asia-Pacific descriptors for obesity and metabolic health status and the National

EvidenceUpdates2017

126. Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study)

Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study) 28619989 2017 06 16 2017 07 19 2017 07 19 1524-4628 48 7 2017 Jul Stroke Stroke Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study). 1877-1883 10.1161/STROKEAHA.116.016274 Many patients receiving thrombolysis for acute (...) ischemic stroke are on prior antiplatelet therapy (APT), which may increase symptomatic intracerebral hemorrhage risk. In a prespecified subgroup analysis, we report comparative effects of different doses of intravenous alteplase according to prior APT use among participants of the international multicenter ENCHANTED study (Enhanced Control of Hypertension and Thrombolysis Stroke Study). Among 3285 alteplase-treated patients (mean age, 66.6 years; 38% women) randomly assigned to low-dose (0.6 mg/kg

EvidenceUpdates2017

127. Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension

Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension 28328237 2017 03 22 2017 07 31 2017 08 09 1535-4970 196 2 2017 Jul 15 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension. 228-239 10.1164/rccm.201611-2365OC Prognostication is important when counseling patients and defining treatment strategies (...) in pulmonary arterial hypertension (PAH). To determine the value of magnetic resonance imaging (MRI) metrics for prediction of mortality in PAH. Consecutive patients with PAH undergoing MRI were identified from the ASPIRE (Assessing the Spectrum of Pulmonary Hypertension Identified at a Referral Centre) pulmonary hypertension registry. During the follow-up period of 42 (range, 17-142) months 576 patients were studied and 221 (38%) died. A derivation cohort (n = 288; 115 deaths) and validation cohort (n

EvidenceUpdates2017

129. Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study.

Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study. Objectives To determine how soon after delivery the risk of post-pregnancy hypertension increases in women with hypertensive disorders of pregnancy and how the risk evolves over time. Design Nationwide register based cohort study. Setting Denmark. Populations 482 972 primiparous women with a first live birth or stillbirth between 1995 and 2012 (cumulative incidence (...) analyses), and 1 025 118 women with at least one live birth or stillbirth between 1978 and 2012 (Cox regression analyses). Main outcome measures 10 year cumulative incidences of post-pregnancy hypertension requiring treatment with prescription drugs, and hazard ratios estimated using Cox regression. Results Of women with a hypertensive disorder of pregnancy in a first pregnancy in their 20s, 14% developed hypertension in the first decade post partum, compared with 4% of women with normotensive first

BMJ2017

130. Lifestyle in progression from hypertensive disorders of pregnancy to chronic hypertension in Nurses' Health Study II: observational cohort study.

Lifestyle in progression from hypertensive disorders of pregnancy to chronic hypertension in Nurses' Health Study II: observational cohort study. Objectives To study the association between lifestyle risk factors and chronic hypertension by history of hypertensive disorders of pregnancy (HDP: gestational hypertension and pre-eclampsia) and investigate the extent to which these risk factors modify the association between HDP and chronic hypertension. Design Prospective cohort study. Setting (...) Nurses' Health Study II (1991-2013). Participants 54 588 parous women aged 32 to 59 years with data on reproductive history and without previous chronic hypertension, stroke, or myocardial infarction. Main outcome measure Chronic hypertension diagnosed by a physician and indicated through nurse participant self report. Multivariable Cox proportional hazards models were used to investigate the development of chronic hypertension contingent on history of HDP and four lifestyle risk factors: post

BMJ2017

132. Foley catheterisation versus oral misoprostol for induction of labour in hypertensive women in India (INFORM): a multicentre, open-label, randomised controlled trial.

Foley catheterisation versus oral misoprostol for induction of labour in hypertensive women in India (INFORM): a multicentre, open-label, randomised controlled trial. BACKGROUND: Between 62 000 and 77 000 women die annually from pre-eclampsia and eclampsia. Prompt delivery, preferably by the vaginal route, is vital for good maternal and neonatal outcomes. Two low-cost interventions-low-dose oral misoprostol tablets and transcervical Foley catheterisation-are already used in low-resource (...) settings. We aimed to compare the relative risks and benefits of these interventions. METHODS: We undertook this multicentre, open-label, randomised controlled trial in two public hospitals in Nagpur, India. Women (aged ≥18 years) who were at 20 weeks' gestation or later with a live fetus and required delivery as a result of pre-eclampsia or hypertension were randomly assigned (1:1), via computer-generated block randomisation (block sizes of four, six, and eight) with concealment by use of opaque

Lancet2017

134. CHA2DS2-VASc Score (Congestive Heart Failure, Hypertension, Age >/=75 [Doubled], Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack [Doubled], Vascular Disease, Age 65-74, Female) for Stroke in Asian Patients With Atrial Fibrillation: A Korean N

CHA2DS2-VASc Score (Congestive Heart Failure, Hypertension, Age >/=75 [Doubled], Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack [Doubled], Vascular Disease, Age 65-74, Female) for Stroke in Asian Patients With Atrial Fibrillation: A Korean N 28455320 2017 04 29 2017 05 23 1524-4628 48 6 2017 Jun Stroke Stroke CHA2DS2-VASc Score (Congestive Heart Failure, Hypertension, Age ≥75 [Doubled], Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack [Doubled], Vascular Disease, Age (...) 65-74, Female) for Stroke in Asian Patients With Atrial Fibrillation: A Korean Nationwide Sample Cohort Study. 1524-1530 10.1161/STROKEAHA.117.016926 The CHA2DS2-VASc stroke score (congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65-74, female) is used in most guidelines for risk stratification in atrial fibrillation (AF), but most data for this score have been derived in Western populations

EvidenceUpdates2017

135. Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice

Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Prescrire IN ENGLISH - Spotlight ''Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice'', 1 June 2017 {1} {1} {1} | | > > > Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |    (...) |   |   |   |   |   |   |  Spotlight Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Hypertension treatment in diabetes patients aims to reduce the risk of complications: cardiovascular events, end-stage renal failure, deterioration of eyesight. Patients with diabetes are exposed to arterial damage, including coronary artery disease and stroke, and damage to the blood capillaries

Prescrire2017

136. Heritability and risks associated with early onset hypertension: multigenerational, prospective analysis in the Framingham Heart Study.

Heritability and risks associated with early onset hypertension: multigenerational, prospective analysis in the Framingham Heart Study. Objective To determine the role of early onset versus late onset hypertension as a risk factor for hypertension in offspring and cardiovascular death. Design Multigenerational, prospective cohort study. Setting Framingham Heart Study. Participants Two generations of community dwelling participants with blood pressure measurements performed at serial (...) examinations spanning six decades: 3614 first generation participants with mortality data and 1635 initially non-hypertensive second generation participants with data available on parental blood pressure. Main outcome measures The main outcome measures were relation of parental early onset hypertension (age <55 years) with incidence of hypertension in offspring, using regression analyses, and relation of age at hypertension onset with cause specific mortality using a case (cardiovascular death) versus

BMJ2017

137. The Dietary Approaches to Stop Hypertension (DASH) diet, Western diet, and risk of gout in men: prospective cohort study.

The Dietary Approaches to Stop Hypertension (DASH) diet, Western diet, and risk of gout in men: prospective cohort study. Objective To prospectively examine the relation between the Dietary Approaches to Stop Hypertension (DASH) and Western diets and risk of gout (ie, the clinical endpoint of hyperuricemia) in men. Design Prospective cohort study. Setting The Health Professionals Follow-up Study. Participants 44 444 men with no history of gout at baseline. Using validated food frequency (...) for gout, adjusting for potential confounders, including age, body mass index, hypertension, diuretic use, and alcohol intake. Results During 26 years of follow-up, 1731 confirmed cases of incident gout were documented. A higher DASH dietary pattern score was associated with a lower risk for gout (adjusted relative risk for extreme fifths 0.68, 95% confidence interval 0.57 to 0.80, P value for trend <0.001). In contrast, a higher Western dietary pattern score was associated with an increased risk

BMJ2017

138. Continuous subcutaneous treprostinil for treatment of pulmonary arterial hypertension

Continuous subcutaneous treprostinil for treatment of pulmonary arterial hypertension Continuous subcutaneous treprostinil for treatment of pulmonary arterial hypertension Continuous subcutaneous treprostinil for treatment of pulmonary arterial hypertension HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Continuous subcutaneous (...) treprostinil for treatment of pulmonary arterial hypertension. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Pulmonary arterial hypertension (PAH) refers to the vascular remodeling of the small pulmonary arteries that is associated with elevated pulmonary arterial pressure (PAP) and eventually right ventricular failure (RVF). Symptoms of PAH begin as shortness of breath at exertion, later progressing to dyspnea with normal activities, and ultimately dyspnea

Health Technology Assessment (HTA) Database.2017

139. Macitentan (pulmonary arterial hypertension) - Benefit assessment according to õ35a Social Code Book V

Macitentan (pulmonary arterial hypertension) - Benefit assessment according to õ35a Social Code Book V Macitentan (pulmonal arterielle Hypertonie): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-67 [Macitentan (pulmonary arterial hypertension) - Benefit assessment according to §35a Social Code Book V] Macitentan (pulmonal arterielle Hypertonie): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-67 [Macitentan (pulmonary arterial hypertension) - Benefit (...) . [Macitentan (pulmonary arterial hypertension) - Benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 476. 2017 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Pyrimidines; Sulfonamides Language Published German Country of organisation Germany English summary There is no English language summary

Health Technology Assessment (HTA) Database.2017

140. Baroreflex activation therapy for drug-resistant hypertension. A single technology assessment

Baroreflex activation therapy for drug-resistant hypertension. A single technology assessment Baroreflex activation therapy for drug-resistant hypertension. A single technology assessment - NIPH Selected items added to basket Close Vis søkefelt How can we help you today? Search for: Søk Menu • • Baroreflex activation therapy for drug-resistant hypertension. A single technology assessment Søk i Folkehelsa.no Search for: Søk Infectious diseases & Vaccines Close Mental & Physical health Close (...) Environment & Lifestyle Close Health in Norway Close Quality and Knowledge Close More topics Close Skip to content Background The Barostim therapy device is an active implantable device which delivers electrical stimulation to the baroreceptors located on the carotid artery with the aim of lowering blood pressure in patients with resistant hypertension. This device for baroreflex activation therapy has been produced as a first generation system (Rheos system), and the currently available second generation

Norwegian Institute of Public Health2017